Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2541 studies found for:    "Leukemia Myeloid"
Show Display Options
Rank Status Study
1 Terminated Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: Zileuton (Zyflo®) Dasatinib (Sprycel®);   Drug: Dosing with Zileuton/Dasatinib in CML;   Drug: Daily dosing of Zileuton/Dasatinib;   Drug: Daily dosing with Zileuton/Dasatinib for CML
2 Recruiting Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Relapsed Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Intervention: Drug: cabozantinib
3 Withdrawn RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
Condition: Chronic Myeloid Leukemia
Interventions: Drug: RAD001;   Drug: Imatinib
4 Recruiting Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Azacitadine;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Lenograstim;   Drug: Filgastrim
5 Unknown  Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: CHR-2797
6 Unknown  Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients
Condition: Acute Myeloid Leukemia
Intervention: Drug: Idarubicin
7 Not yet recruiting Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Biological: NK Cells + Chemotherapy Starting
8 Active, not recruiting Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Condition: Chronic Myeloid Leukemia
Intervention:
9 Recruiting Regional Central Database Recording of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: Practices evaluation
10 Completed
Has Results
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
Conditions: Chronic Myeloid Leukemia;   Philadelphia-Positive Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Imatinib
11 Completed
Has Results
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib
12 Completed A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients
Condition: Acute Myeloid Leukemia
Intervention: Drug: OCV-501
13 Completed Role of PTK-7 in Acute Myeloid Leukemias
Condition: Acute Myeloid Leukemia
Interventions: Other: Bone marrow aspiration;   Other: Blood sampling
14 Recruiting Bosutinib in Elderly Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Bosutinib
15 Terminated
Has Results
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Low-dose cytarabine alone
16 Not yet recruiting Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: guadecitabine;   Drug: Treatment Choice (TC)
17 Completed
Has Results
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
Conditions: Chronic Myeloid Leukemia;   Philadelphia-Positive Myeloid Leukemia
Intervention: Drug: Dasatinib
18 Unknown  Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat
19 Terminated Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)
Condition: Acute Myelogenous Leukemia
Intervention: Drug: Troxatyl™ (Cytotoxic Chemotherapeutic)
20 Recruiting A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia, in Relapse;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: GO-203-2c;   Drug: GO-203-2c + Decitabine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.